Clostridium difficile and the surgeon

American Surgeon

Volumn 76, Issue 3, 2010, Pages 235-244

  Stanley, J Daniel ^a   Burns, R Phillip ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACITRACIN; COLESTYRAMINE; ENEMA; FUSIDIC ACID; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; METRONIDAZOLE; NITAZOXANIDE; RIFALAZIL; RIFAMPICIN; RIFAXIMIN; TEICOPLANIN; TOLEVAMER; VANCOMYCIN;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; DIAGNOSTIC TEST; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG PREFERENCE; ENZYME IMMUNOASSAY; FECES CULTURE; FEVER; GASTROINTESTINAL SURGERY; HUMAN; INFECTION SENSITIVITY; LEUKOCYTOSIS; NAUSEA; NOTE; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PREVALENCE; RECURRENCE RISK; RECURRENT INFECTION; RISK FACTOR; RISK REDUCTION; SURGEON; TRANSPLANTATION; TREATMENT INDICATION;

ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; COLECTOMY; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; HUMANS; ILEOSTOMY; METRONIDAZOLE; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RISK FACTORS; SURGICAL PROCEDURES, OPERATIVE; VIRULENCE;

EID: 77949516928     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (61)

1. Bartlett JG. Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis 2008;46(suppl 1):S4-11.
2. Hurley BW, Nguyen CC. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch Intern Med 2002;162:2177-84.
3. Kyne L, Farrell RJ, Kelly CP. Clostridium difficile. Gastroenterol Clin North Am 2001;30:753-77, ix-x.
4. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-associated diarrhea: a review. Arch Intern Med 2001;161:525-33.
5. Greenstein AJ, Byrn JC, Zhang LP, et al. Risk factors for the development of fulminant Clostridium difficile colitis. Surgery 2008;143:623-9.
6. Halsey J. Current and future treatment modalities for Clostridium difficile-associated disease. Am J Health Syst Pharm 2008;65:705-15.
7. Adams SD, Mercer DW. Fulminant Clostridium difficile colitis. Curr Opin Crit Care 2007;13:450-5.
8. Centers for Disease Control and Prevention (CDC). Severe Clostridium difficile-associated disease in populations previously at low risk - four states, 2005. MMWR Morb Mortal Wkly Rep 2005;54:1201-5.
9. Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008;47:1162-70.
10. Aslam S, Musher DM. An update on diagnosis, treatment, and prevention of Clostridium difficile-associated disease. Gastroenterol Clin North Am 2006;35:315-35.
11. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002;235:363-72.
12. Longo WE, Mazuski JE, Virgo KS, et al. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum 2004;47:1620-6.
13. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9.
14. Giannasca PJ, Warny M. Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine 2004;22:848-56.
15. Lamontagne F, Labbé AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007;245:267-72.
16. Mazuski J. Clostridium difficile colitis. Probl Gen Surg 2002;19:121-32.
17. Hookman P, Barkin JS. Review: Clostridium difficile-associated disorders/diarrhea and Clostridium difficile colitis: the emergence of a more virulent era. Dig Dis Sci 2007;52:1071-5.
18. Pepin J, Vo TT, Boutros M, et al. Risk factors for mortality following emergency colectomy for fulminant Clostridium difficile infection. Dis Colon Rectum 2009;52:400-5.
19. Byrn JC, Maun DC, Gingold DS, et al. Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg 2008;143:150-4; discussion 155.
20. Koss K, Clark MA, Sanders DS, et al. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis 2005;8:149-54.
21. Hui RK, Zeng F, Chan CM, et al. Reverse transcriptase PCR diagnostic assay for the coronavirus associated with severe acute respiratory syndrome. J Clin Microbiol 2004;42:1994-9.
22. Barbut F, Kajzer C, Planas N, Petit JC. Comparison of three enzyme immunoassays, a cytotoxicity assay, and toxigenic culture for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol 1993;31:963-7.
23. Reller ME, Lema CA, Perl TM, et al. Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic Clostridium difficile. J Clin Microbiol 2007;45:3601-5.
24. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008;46(suppl 1):S12-8.
25. Mohan SS, McDermott BP, Parchuri S, Cunha BA. Lack of value of repeat stool testing for Clostridium difficile toxin. Am J Med, 2006. 119:356.e7-8.
26. Wolfhagen MJ, Meijer K, Fluit AC, et al. Clinical significance of Clostridium difficile and its toxins in faeces of immunocompromised children. Gut 1994;35:1608-12.
27. Zheng L, Keller SF, Lyerly DM, et al. Multicenter evaluation of a new screening test that detects Clostridium difficile in fecal specimens. J Clin Microbiol 2004;42:3837-40.
28. Ticehurst JR, Aird DZ, Dam LM, et al. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol 2006;44:1145-9.
29. Morris JB, Zollinger RM Jr, Stellato TA. Role of surgery in antibiotic-induced pseudomembranous enterocolitis. Am J Surg 1990;160:535-9.
30. Medich DS, Lee KK, Simmons RL, et al. Laparotomy for fulminant pseudomembranous colitis. Arch Surg 1992;127:847-52; discussion 852-3.
31. Malnick SD, Zimhony O. Treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother 2002;36:1767-75.
32. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40:1591-7.
33. Musher DM, Logan N, Mehendiratta V, et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007;59:705-10.
34. Sunenshine RH, McDonald LC. Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med 2006;73:187-97.
35. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002;35:690-6.
36. Bouza ED, Mohammed M, Peppe R, et al. Clositridium difficile - Changing Epidemiology and Treatment Options. 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 2008. Abstract.
37. Garey KW, Salazar M, Shah D, et al. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother 2008;42:827-35.
38. Taylor C, Tummala S, Molrine D, et al. Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine 2008;26:3404-9.
39. Fekety R, McFarland LV, Surawicz CM, et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997;24:324-33.
40. Jobe BA, Grasley A, Deveney KE, et al. Clostridium difficile colitis: an increasing hospital-acquired illness. Am J Surg 1995;169:480-3.
41. Bradbury AW, Barrett S. Surgical aspects of Clostridium difficile colitis. Br J Surg 1997;84:150-9.
42. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006;145:758-64.
43. Ricciardi R, Ogilvie JW Jr, Roberts PL, et al. Epidemiology of Clostridium difficile colitis in hospitalized patients with inflammatory bowel diseases. Dis Colon Rectum 2009;52:40-5.
44. What Is Clostridium difficile? Frequently Asked Questions: Information for Healthcare Providers 2004. July 22, 2005. Available at: www.cdc.gov/ncidod/dhqp/id-CdiffFAQ-HCP.html. Accessed December 28, 2008.
45. Gerding DN. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis 2004;38:646-8.
46. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273-80.
47. Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. N Engl J Med 2008;359:1932-40.
48. Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007;335:80.
49. Grundfest-Broniatowski S, Quader M, Alexander F, et al. Clostridium difficile colitis in the critically ill. Dis Colon Rectum 1996;39:619-23.
50. Lipsett PA, Samantaray DK, Tam ML, et al. Pseudomembranous colitis: a surgical disease? Surgery 1994;116:491-6.
51. Clabots CR, Johnson S, Olson MM, et al. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 1992;166:561-7.
52. Fazio VW. Toxic megacolon in ulcerative colitis and Crohn's colitis. Clin Gastroenterol 1980;9:389-407.
53. Berman L, Carling T, Fitzgerald TN, et al. Defining surgical therapy for pseudomembranous colitis with toxic megacolon. J Clin Gastroenterol 2008;42:476-80.
54. Ali SO, Welch JP, Dring RJ. Early surgical intervention for fulminant pseudomembranous colitis. Am Surg 2008;74:20-6.
55. Hall JF, Berger D. Outcome of colectomy for Clostridium difficile colitis: a plea for early surgical management. Am J Surg 2008;196:384-8.
56. Noblett SE, Welfare M, Seymour K. The role of surgery in Clostridium difficile colitis. BMJ 2009;338:b1563.
57. Synnott K, Mealy K, Merry C, et al. Timing of surgery for fulminating pseudomembranous colitis. Br J Surg 1998;85:229-31.
58. Morris LL, Villalba MR, Glover JL. Management of pseudomembranous colitis. Am Surg 1994;60:548-51; discussion 551-2.
59. Viswanath YK, Griffiths CD. The role of surgery in pseudomembranous enterocolitis. Postgrad Med J 1998;74:216-9.
60. Williams RN, Hemingway D, Miller AS. Enteral Clostridium difficile, an emerging cause for high output ileostomy. J Clin Pathol, 2009;62:951-3.
61. Beckwith PS, Wolff BG, Frazee RC. Ileorectostomy in the older patient. Dis Colon Rectum 1992;35:301-4.